Literature DB >> 3215194

Cardiomyopathy associated with carnitine loss in kidneys and small intestine.

R Rodrigues Pereira1, H R Scholte, I E Luyt-Houwen, M H Vaandrager-Verduin.   

Abstract

A boy was first seen at the age of 1 year on account of congestive cardiomyopathy. Growth and development had been normal. Total plasma carnitine was extremely low (1.8 mumol/l; normal range: 25-64 mumol/l). No hypoglycaemia, lactic acidaemia or dicarboxylic aciduria were found. Other laboratory findings were unremarkable except for a slight deficiency in iron, vitamin D and vitamin E. Total muscle carnitine was 1.5% of normal; however, no signs or symptoms of myopathy could be detected. After carnitine loading, liver carnitine increased to 24% of normal. Isolated muscle mitochondria showed decreased oxidative capacity with all substrates tested. Stimulation of O2 uptake by adenosine diphosphate (ADP) was decreased. After loading with both intravenous and oral carnitine, there was a rise in plasma carnitine and a rapid loss in the urine and the faeces. These findings suggest a defect in the brush border carnitine transport system of the kidneys and of the small intestine. Renal clearance of carnitine was abnormally high. Therapy with 1 g oral L-carnitine/kg per day was instituted without any problems and the cardiac disease resolved within 3 months. The parents and the patient's five sibs also had low plasma carnitine but displayed no cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3215194     DOI: 10.1007/bf00441399

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  [Carnitine deficiency: a treatable cause of cardiomyopathy in children (author's transl)].

Authors:  V Regitz; R J Hodach; A L Shug
Journal:  Klin Wochenschr       Date:  1982-04-15

2.  Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy.

Authors:  M E Tripp; M L Katcher; H A Peters; E F Gilbert; S Arya; R J Hodach; A L Shug
Journal:  N Engl J Med       Date:  1981-08-13       Impact factor: 91.245

3.  Adenine nucleotide transport in sonic submitochondrial particles. Kinetic properties and binding of specific inhibitors.

Authors:  G J Lauquin; C Villiers; J W Michejda; L V Hryniewiecka; P V Vignais
Journal:  Biochim Biophys Acta       Date:  1977-05-11

4.  Carnitine metabolism and inborn errors.

Authors:  A G Engel; C J Rebouche
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

5.  Primary systemic carnitine deficiency. II. Renal handling of carnitine.

Authors:  A G Engel; C J Rebouche; D M Wilson; A M Glasgow; C A Romshe; R P Cruse
Journal:  Neurology       Date:  1981-07       Impact factor: 9.910

6.  Dietary-dependent carnitine deficiency as a cause of nonketotic hypoglycemia in an infant.

Authors:  A E Slonim; P R Borum; K Tanaka; C A Stanley; A G Kasselberg; H L Greene; I M Burr
Journal:  J Pediatr       Date:  1981-10       Impact factor: 4.406

7.  Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels of free fatty acids and beta-hydroxybutyrate.

Authors:  J Frohlich; D W Seccombe; P Hahn; P Dodek; I Hynie
Journal:  Metabolism       Date:  1978-05       Impact factor: 8.694

Review 8.  Carnitine--metabolism and functions.

Authors:  J Bremer
Journal:  Physiol Rev       Date:  1983-10       Impact factor: 37.312

9.  Systemic carnitine deficiency--a treatable inherited lipid-storage disease presenting as Reye's syndrome.

Authors:  P R Chapoy; C Angelini; W J Brown; J E Stiff; A L Shug; S D Cederbaum
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

10.  Carnitine deficiency presenting as familial cardiomyopathy: a treatable defect in carnitine transport.

Authors:  L J Waber; D Valle; C Neill; S DiMauro; A Shug
Journal:  J Pediatr       Date:  1982-11       Impact factor: 4.406

View more
  5 in total

Review 1.  Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects.

Authors:  Stephanie E Reuter; Allan M Evans
Journal:  Clin Pharmacokinet       Date:  2012-09-01       Impact factor: 6.447

2.  Effect of propionyl-L-carnitine in a rat model of peripheral arteriopathy: a functional, histologic, and NMR spectroscopic study.

Authors:  N Corsico; A Nardone; M R Lucreziotti; L G Spagnoli; D Pesce; T Aureli; M E Di Cocco; A Miccheli; F Conti; E Arrigoni Martelli
Journal:  Cardiovasc Drugs Ther       Date:  1993-04       Impact factor: 3.727

3.  Cardiomyopathy in propionic acidaemia.

Authors:  A F Massoud; J V Leonard
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

4.  Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency.

Authors:  J Miyagawa; M Kuwajima; T Hanafusa; K Ozaki; H Fujimura; A Ono; R Uenaka; I Narama; T Oue; K Yamamoto
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Characterization of the endogenous carnitine transport and expression of a rat renal Na(+)-dependent carnitine transport system in Xenopus laevis oocytes.

Authors:  S Berardi; B Hagenbuch; E Carafoli; S Krähenbühl
Journal:  Biochem J       Date:  1995-07-15       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.